Novo To Secure Licensing Or M&A Deal By Mid-2018

Who is on Scrip’s list of potential licensing partners and M&A targets for Novo Nordisk, now that the company has renewed its hunt for new products to add to its hematology portfolio?

Jigsaw
Novo Nordisk seeks new deal in next six months to fill pipeline gap • Source: Shutterstock

More from Earnings

More from Business